Patents Assigned to UAB Research Foundation
  • Patent number: 11897845
    Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: February 13, 2024
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • Publication number: 20240011047
    Abstract: In one aspect, the present invention provides recombinant polynucleotides. In some embodiments, the recombinant polynucleotides comprise a cytomegalovirus (CMV) genome, or a portion thereof, and a nucleic acid sequence encoding an antigen, wherein the CMV genome or portion thereof comprises a mutation within a interleukin-10-like gene sequence. Methods for preventing and treating diseases such as infectious diseases and cancer are also provided herein.
    Type: Application
    Filed: December 12, 2022
    Publication date: January 11, 2024
    Applicants: The Regents of the University of California, The UAB Research Foundation
    Inventors: Peter Barry, Dennis Hartigan-O'Connor, Ellen Sparger, William Chang, Mark Walter, Corey Miller
  • Patent number: 11866416
    Abstract: The present invention is related to the inhibition of the formation of Streptococci biofilms through the inhibition of glucosyl transferase (Gtf). Compounds, compositions and methods for inhibiting Streptococcus biofilm formation, as well as for preventing, inhibiting and/or treating the formation of dental caries, and methods of identifying compounds that prevent, inhibit and/or treat the formation of dental caries are provided.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: January 9, 2024
    Assignee: UAB Research Foundation
    Inventors: Sadanandan E. Velu, Hui Wu, Qiong Zhang, Bhavitavya Nijampatnam
  • Patent number: 11858966
    Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.
    Type: Grant
    Filed: February 17, 2022
    Date of Patent: January 2, 2024
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Michael Niederweis, Mikhail Pavlenok
  • Patent number: 11844817
    Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, 5 that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: December 19, 2023
    Assignee: The UAB Research Foundation
    Inventors: Charitharth Vivek Lal, Namasivayam Ambalavanan, Amit Gaggar, Casey Morrow
  • Patent number: 11844572
    Abstract: The present disclosure provides an improved method for photobleaching an eye of a subject. The disclosed method may be used in a number of psychophysical test methods, including, but not limited to, measurement of dark adaptation. The improved method for photobleaching involves at least one of the following improvements: (i) the use of a bleaching light emitting a particular wavelength of light or a tailored spectrum of wavelengths; (ii) restricting or otherwise spatially tailoring the region of the retina that is subject to photobleaching; and (iii) utilizing a bleaching light having an intensity that is at or below the intensity of ambient daylight. The present disclosure additionally provides a combination of a photobleaching light and an apparatus to administer a psychophysical test suitable for use in practicing the disclosed methods.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: December 19, 2023
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: John G. Edwards, Gregory R. Jackson
  • Patent number: 11807685
    Abstract: Disclosed is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: November 7, 2023
    Assignee: The UAB Research Foundation
    Inventor: Xiaoguang Margaret Liu
  • Patent number: 11806392
    Abstract: The present embodiments provide compositions and methods related to novel recombinant protein immunogens, comprising specific portions of alpha helical domains (aHD) and proline rich regions (PRD) of pneumococcal surface protein A (PspA), which portions are linked to provide aHD-PRD constructs. The aHD and PRD proteins constituting the aHD-PRD constructs are selected to maximize cross-reactivity and provide protection against a broad spectrum of pneumococcal serotypes. Immunogenic compositions, including vaccines, comprising at least one aHD PRD construct may also include a non-linked aHD portion. Also provided are recombinant nucleic acid molecules that encode aHD-PRD constructs, vectors and recombinant host cells containing such molecules, aHD-PRD expression products, use of such nucleic acid molecules to express aHD-PRD constructs by recombinant techniques, and use of the expression products to elicit an immune or protective response against pneumococcal disease in a suitable host.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: November 7, 2023
    Assignees: The UAB Research Foundation, The University of Tokyo
    Inventors: David E. Briles, Hiroshi Kiyono, Robert Kneller, Reshmi Mukerji, Kristopher Genschmer, Yoshikazu Yuki
  • Patent number: 11793203
    Abstract: Compositions and methods of use thereof for delivering an insecticide to water-borne insect larvae are provided. Whereas individual cells of the insecticidal bacteria such as Bacillus thuringiensis israelensis (Bti), are effective in killing insect larvae when ingested by same, their use in aqueous environments is restricted by the time that the bacterial cells remain suspended in water and hence available for ingestion by the larvae. To increase the time that the insecticidal bacteria remain in suspension, it has now been found advantageous to mix bacterial suspensions with nanoparticles comprising carbon that attach to the external surface of the cells.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 24, 2023
    Assignee: The UAB Research Foundation
    Inventors: Stephen A. Watts, Andrei V. Stanishevsky, Mickie L. Powell, Robert Novak
  • Patent number: 11767346
    Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (for example, variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: September 26, 2023
    Assignees: University of Florida Research Foundation, Incorporated, The UAB Research Foundation
    Inventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Paul D. Gamlin
  • Patent number: 11752153
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: September 12, 2023
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Patent number: 11753374
    Abstract: The present disclosure is concerned with biaryl aminomaleimide compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: September 12, 2023
    Assignees: Southern Reserach Institute, The UAB Research Foundation, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Mark J. Suto, Bini Mathew, Anupam Agarwal, Amie M. Traylor
  • Patent number: 11752138
    Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: September 12, 2023
    Assignees: VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Matthew Hall, Daniel J. Urban, John Knight, Ross Holmes, Kyle David Wood, Alex Waterson, Victor M. Darley-Usmar, Leonard M. Neckers
  • Publication number: 20230263426
    Abstract: The present disclosure relates to a method of detecting airflow obstruction using one or more novel metrics associated with a spirometry reading for a subject. The method includes obtaining spirometry data from a subject, generating a first measurement curve and a second measurement curve based on the obtained data for the subject, performing at least a first curve-fitting on the first measurement curve using a Least Absolute Residuals algorithm to estimate a function which closely approximates the spirometry data for the subject by minimizing a sum of absolute deviation, determining a first metric that describes a rate of volume increase based on the estimated function, comparing the first metric to one or more threshold values, and determining a presence or absence of airflow obstruction for the subject based on the comparison of the first metric to the one or more threshold values.
    Type: Application
    Filed: August 13, 2021
    Publication date: August 24, 2023
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Surya P. Bhatt, Arie Nakhmani, Sandeep Bodduluri
  • Publication number: 20230218596
    Abstract: The invention relates to treatments for coronavirus infections by administering a neutrophil elastase inhibitor, such as alvelestat.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 13, 2023
    Applicants: MEREO BIOPHARMA 4 LIMITED, THE UAB RESEARCH FOUNDATION
    Inventors: Jacqueline PARKIN, James Michael WELLS, Mark DRANSFIELD
  • Publication number: 20230172932
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 8, 2023
    Applicants: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Publication number: 20230159542
    Abstract: This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 25, 2023
    Applicants: THE UAB RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTE, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Louis B. Nabors, Natalia Filippova, Xiuhua Yang, Subramaniam Ananthan, Vibha Pathak, Peter King
  • Publication number: 20230154004
    Abstract: Relationships between morphological changes to an eye due to intraocular pressure changes and blood perfusion and nerve function changes in the retina are determined by colocalizing retinal perfusion data, optic nerve head (ONH) mechanical deformation data, visual field data and nerve fiber data. Perfusion and nerve function changes from intraocular pressure (IOP) changes are determined by colocalizing retinal perfusion data with ONH mechanical deformation data, visual field data and nerve fiber data. Optical coherence tomography-angiography (OCT-A) can be used to generate retinal perfusion data, mechanical deformation data for an imaged volume, and nerve fiber data. A three-dimensional model (e.g., connectivity map or connectivity model) of the vasculature and nerve fibers can be generated from the OCT-A imaging data and used to predict changes in blood perfusion and nerve function in various areas of the retina due to IOP-induced mechanical deformations.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 18, 2023
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Massimo Antonio Fazio, Christopher Anthony Girkin, Andrea Ramazzotti
  • Patent number: 11643668
    Abstract: Provided herein are CRISPR/Cas9 complexes and method of using same.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: May 9, 2023
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Tim Townes, Lei Ding, Chia-Wei Chang
  • Patent number: 11634764
    Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: April 25, 2023
    Assignees: University of Washington, The UAB Research Foundation
    Inventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran